Investigators conducted a high-throughput screen to identify molecules that could enhance primary human NK cell function. After compound validation, they investigated the effect of the top-performing compounds on dysfunctional NK cells that were generated by a newly developed in vitro platform.
[Journal of Immunotherapy of Cancer]
